In a few years time the next generation CAR-T cell therapies are going to look and behave very…
A look at some new developments in CAR-T cell therapy for gliomas
We have heard much over the last decade or so about the impact of the microbiome on responses to…
The next generation of CAR-T cell therapy will require out of the box thinking
Some promising new early developments are coming through in AML and T-ALL - what's the skinny?
Insights from Transplantation & Cellular Therapy (TCT) meeting on the next generation of CAR T cells
In this post we look at an emerging research area that will be important to address if CAR T cell therapy is to be effective in solid tumours
CAR T cell therapy for solid tumors is the cancer new product development equivalent of the quest for the "Holy Grail."
Interview with Dr Carl June on what the next decade holds for CAR T cells, cell therapy and genome engineering
Interview with Prof John Gribben at second European EHA EBMT CAR T cell therapy meeting in Sitges, Spain
Commentary on Day 2 of the EHA EBMT 2nd European CAR T cell meeting
Commentary on first day of EHA EBMT European CAR T meeting in Sitges, Spain
A look at the γδ T cell competitive landscape with cell therapies, antibodies and bispecifics in early stage development
A look at what Gamida Cell, an up and coming cellular and innate immunotherapy company are up to...
In this post, we take a look at new clinical and scientific findings that may pave the way forward for the future in the CAR T cell space
What did Dr Grupp and Dr Komanduri learn from participation in the CAR T cell therapy trials?
Insight from BMT Tandem 2017 meeting into latest Cell Therapy data
Finding new ways to optimise CAR T cell therapy in CLL and solid tumours may be closer than you think...
Trends in Haplo stem cell transplants may impact Bellicum Pharmaceuticals adjunct T Cell therapy BPX–501
Could immune resistance be reversed or prevented by the addition of appropriate checkpoint blockade? Which ones matter though, that is the critical question?
Interview at BMT Tandem 2016 about a novel cell therapy that could compete with or replace CAR T cell therapy
Commentary on presentation by Dr Philippe Armand at BMT Tandem meeting on “Checkpoint Blockade in SCT, Data & Hope, Promise & Peril”
Interview with Dr Michael Jensen on CD19 CAR T Cell Therapy
Interview at BMT Tandem 2016 with Dr David Porter U Penn on CD19 targeted CAR T cell therapy in CLL
Preview of noteworthy sessions at 2016 BMT Tandem meeting in Honolulu, Hawaii
What are some of the strategic trends and drivers in the Graft versus Host Disease (GvHD) space at #BMTTandem16?
A novel cell therapy approach uses T cells targeting multiple tumor-associated antigens.
Dr Krishna Komanduri discusses some of the best abstracts at the 2015 BMT Tandem meeting in San Diego.
University College London (UCL) is leading the way in European clinical trials of CAR T Cell therapies that target CD19.
Does checkpoint blockade with CTLA4 have a role to play in hematologic malignancies?